Treatment options for relapsed Waldenstrom's Macroglobulinemia

被引：0
|
作者：
Grunenberg, Alexander [1 ]
Buske, Christian [1 ,2 ]
机构：
[1] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[2] Univ Hosp Ulm, CCC Ulm, Inst Expt Canc Res, Ulm, Germany
来源：
HEMASPHERE | 2019年 / 3卷
关键词：
RITUXIMAB; IBRUTINIB;
D O I：
10.1097/HS9.0000000000000221
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Take home messages There are several treatment approaches available for relapsed WM patients. The choice of treatment for relapsed patients should be adapted to the fitness of patients, the previous therapy and the duration of response after last treatment. Rituximab based regimens, Bortezomib containing regimens, and Ibrutinib are well tolerated and efficient treatment options in relapsed WM patients. The future goal is the development of chemotherapy-free approaches which are active independent from the genotype and are applied for a limited duration of time.
引用
收藏
页码：65 / 67
页数：3
相关论文
共 50 条
  • [1] Treatment options in Waldenstrom's macroglobulinemia
    Björkholm, M
    [J]. CLINICAL LYMPHOMA, 2004, 5 (03): : 155 - 162
  • [2] Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib
    Dimopoulos, Meletios A.
    Anagnostopoulos, Athanasios
    Kyrtsonis, Maria Christina
    Castritis, Efstathios
    Bitsaktsis, Athanasios
    Pangalis, Gerassimos A.
    [J]. HAEMATOLOGICA, 2005, 90 (12) : 1655 - 1658
  • [3] Treatment of relapsed and refractory Waldenstrom Macroglobulinemia
    Amaador, Karima
    Kersten, Marie J.
    Minnema, Monique C.
    Vos, Josephine M., I
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 (01) : 30 - 41
  • [4] Current treatment options for Waldenstrom macroglobulinemia
    Vijay, Arun
    Gertz, Morie A.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (04): : 219 - 229
  • [5] Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (02) : 197 - 205
  • [6] Bortezomib in Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Chen, Christine
    Kouroukis, C. Tom
    White, Darrell
    Voralia, Michael
    Stadtmauer, Edward
    Stewart, A. Keith
    Wright, John J.
    Powers, Jean
    Walsh, Wendy
    Eisenhauer, Elizabeth
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (01): : 74 - 76
  • [7] The Management of Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Garcia-Sanz, Ramon
    Tedeschi, Alessandra
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (04) : 727 - 749
  • [8] Waldenstrom's macroglobulinemia: Treatment approaches for newly diagnosed and relapsed disease
    Hodge, Lucy S.
    Ansell, Stephen M.
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2013, 49 (01) : 19 - 23
  • [9] Current options to manage Waldenstrom's macroglobulinemia
    Benevolo, Giulia
    Nicolosi, Maura
    Santambrogio, Elisa
    Vitolo, Umberto
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (07) : 637 - 647
  • [10] Treatment of Waldenstrom's macroglobulinemia
    Dimopoulos M.A.
    Anagnostopoulos A.
    [J]. Current Treatment Options in Oncology, 2007, 8 (2) : 144 - 153
12345